RASSF2 is a recently identified member of a class of novel tumour suppressor genes, all containing a ras-association domain. RASSF2 resides at 20p13, a region frequently lost in human cancers. In this report we investigated methylation status of the RASSF2 promoter CpG island in a series of breast, ovarian and non-small cell lung cancers (NSCLC). RASSF2 was frequently methylated in breast tumour cell lines (65%, 13/20) and in primary breast tumours (38%, 15/40). RASSF2 expression could be switched back on in methylated breast tumour cell lines after treatment with 5 0 -aza-2 0 deoxycytidine. RASSF2 was also frequently methylated in NSCLC tumours (44%, (22/50). The small number of corresponding normal breast and lung tissue DNA samples analysed were unmethylated. We also did not detect RASSF2 methylation in ovarian tumours (0/17). Furthermore no mutations were found in the coding region of RASSF2 in these ovarian tumours. We identified a highly conserved putative bipartite nuclear localization signal (NLS) and demonstrated that endogenous RASSF2 localized to the nucleus. Mutation of the putative NLS abolished the nuclear localization. RASSF2 suppressed breast tumour cell growth in vitro and in vivo, while the ability of NLSmutant RASSF2 to suppress growth was much diminished. Hence we demonstrate that RASSF2 has a functional NLS that is important for its tumour suppressor gene function. Our data from this and a previous report indicate that RASSF2 is frequently methylated in colorectal, breast and NSCLC tumours. We have identified RASSF2 as a novel methylation marker for multiple malignancies and it has the potential to be developed into a valuable marker for screening several cancers in parallel using promoter hypermethylation profiles.
RASSF2 is a recently identified member of a class of novel tumour suppressor genes, all containing a ras-association domain. RASSF2 resides at 20p13, a region frequently lost in human cancers. In this report we investigated methylation status of the RASSF2 promoter CpG island in a series of breast, ovarian and non-small cell lung cancers (NSCLC). RASSF2 was frequently methylated in breast tumour cell lines (65%, 13/20) and in primary breast tumours (38%, 15/40). RASSF2 expression could be switched back on in methylated breast tumour cell lines after treatment with 5 0 -aza-2 0 deoxycytidine. RASSF2 was also frequently methylated in NSCLC tumours (44%, (22/50) . The small number of corresponding normal breast and lung tissue DNA samples analysed were unmethylated. We also did not detect RASSF2 methylation in ovarian tumours (0/17). Furthermore no mutations were found in the coding region of RASSF2 in these ovarian tumours. We identified a highly conserved putative bipartite nuclear localization signal (NLS) and demonstrated that endogenous RASSF2 localized to the nucleus. Mutation of the putative NLS abolished the nuclear localization. RASSF2 suppressed breast tumour cell growth in vitro and in vivo, while the ability of NLSmutant RASSF2 to suppress growth was much diminished. Hence we demonstrate that RASSF2 has a functional NLS that is important for its tumour suppressor gene function. Our data from this and a previous report indicate that RASSF2 is frequently methylated in colorectal, breast and NSCLC tumours. We have identified RASSF2 as a novel methylation marker for multiple malignancies and it has the potential to be developed into a valuable marker for screening several cancers in parallel using promoter hypermethylation profiles.
Introduction
Epigenetic silencing of tumour suppressor genes plays an important role in the development of many cancer types. Identification of genes that are inactivated by promoter region CpG island hypermethylation will lead not only to insights into novel disease mechanisms but also to development of new diagnostic molecular markers and potential reactivation therapies. We have identified members of a novel family of genes that contain a ras-association domain (reviewed in Agathanggelou et al., 2005; Hesson et al., 2007) . So far the Ras-association domain family (RASSF) of genes contains six members, namely, RASSF1 located at 3p21.3, RASSF2 located at 20p13, RASSF3 located at 12q14.1, AD037 (also known as RASSF4) located at 10q11.21, NORE1 located at 1q32.1 and RASSF6 at 4q21.21. RASSF1 was identified from a region of overlapping homozygous deletions at 3p21.3 in lung and breast tumour cell lines (Dammann et al., 2000; Lerman and Minna, 2000; Agathanggelou et al., 2001; Burbee et al., 2001) . Expression of isoform A of RASSF1 is frequently lost following methylation of its promoter in various adult and childhood cancers (reviewed in Agathanggelou et al., 2005) . So far RASSF1A is thought to play an important role in microtubule stability, it has also shown to be involved in cell cycle regulation, apoptosis and cell migration (see Agathanggelou et al., 2005; Dallol et al., 2005) . RASSF1A has also been shown to be part of a complex similar to the Drosophila Hippo/Salvador/Lats tumour suppressor pathway (Guo et al., 2007) . Rassf1a knock-out mice showed increased susceptibility to spontaneous and carcinogen-induced tumour formation van der Weyden et al., 2005) .
While there are other putative transcripts from the RASSF2 locus, the longest and most abundant is the isoform that has previously been known as RASSF2A, and will be hereafter referred to as RASSF2.
As well as RASSF1A, RASSF2 (Hesson et al., 2005) , AD037/RASSF4 (Eckfeld et al., 2004) and NORE1A (Hesson et al., 2003; Irimia et al., 2004) are also epigenetically inactivated in tumours, while RASSF3 (Tommasi et al., 2002; Hesson et al., 2004) and RASSF6 (Allen et al., 2007) are not methylated. We have recently demonstrated that RASSF2 is frequently methylated in colorectal tumours and adenomas and showed that methylation was cancer specific (Hesson et al., 2005) . Hence, RASSF2 methylation is a potential molecular marker for early detection of colorectal cancer. RASSF2 protein expression is frequently downregulated in human lung tumour cell lines including non-small cell lung cancer (NSCLC) (Vos et al., 2003) . Using array-based comparative genomic hybridization in ovarian tumour cell lines Lambros et al. (2005) identified regions of deletions including homozygous deletions on several chromosomes. Candidate tumour suppressor genes localized to these regions included CDKN2C and MADHIP (1p32.3), WW domain protein WWOX (16q23.1) and RASSF2 (20p13) .
In this report we determined the methylation status of RASSF2 in breast, NSCLC and ovarian tumours. We also undertook experiments to determine tumour suppression properties of RASSF2 and characterized a putative NLS in the RASSF2 sequence.
Results and discussion
Previously we identified RASSF2 as a member of the recently discovered RASSF family of Ras effectors/ tumour suppressors and demonstrated that it binds directly to K-Ras via the Ras effector domain (Vos et al., 2003; Hesson et al., 2005) . K-Ras is a member of a family of oncoproteins that play an important role in many biological processes (Rommel and Hafen, 1998; Malumbres and Barbacid, 2003; Schubbert et al., 2007) . These abilities are mediated by the ability of RAS proteins to interact with a wide range of effector proteins (Shields et al., 2000; Cox and Der, 2003) ; for example via signalling through phosphatidylinositol 3-kinase and AKT, RAS proteins can induce cell division and oncogenesis, whereas interactions with RASSF2 can mediate apoptosis and cell cycle arrest (Vos et al., 2003) . We had previously demonstrated that RASSF2 was frequently methylated in colorectal tumours and adenomas (Hesson et al., 2005) and that methylation was tumour specific. Furthermore, using the same sets of methylation primers as in Hesson et al. (2005) , two recent reports (Park et al., 2007; Zhang et al., 2007) have demonstrated that methylation of RASSF2 corresponds to loss of expression in primary colorectal and nasopharyngeal tumours as well as tumour cell lines.
RASSF2 methylation analysis in breast tumour cell lines
In this report we used combined bisulphite restriction analysis (CoBRA) (Hesson et al., 2005) and bisulphite sequencing to demonstrate for the first time the methylation status of RASSF2 promoter region CpG island in a series of breast tumour cell lines. RASSF2 was methylated in 13 of 20 (65%) of these breast tumour Figure 1 (a) Frequent methylation of the RASSF2 CpG island is observed in breast tumour cell lines as determined by CoBRA digestion of PCR products. Sodium bisulphite modification was performed as described previously (Agathanggelou et al., 2001) . The primers and conditions for the PCR have been described previously (Hesson et al., 2005) . PCR products were then assayed by digestion with TaqI or BstUI for 2 h at 65 or 60 1C, respectively. (b) Direct bisulphite sequencing of the RASSF2 CpG island in breast tumour cell lines. CG dinucleotides within the amplification region are numbered 1-23. The underlined CpGs are contained within BstUI or TaqI recognition sequences. White and black squares represent unmethylated and methylated CpGs, respectively. (c) Expression of RASSF2 in breast tumour cell lines. RASSF2 CpG island hypermethylation corresponds with loss of RASSF2 expression. Expression was restored after treatment with the demethylating agent 5 0 -aza-2 0 deoxycytidine (5-aza-2dC 2.5 mM; Sigma (Poole, UK), media replaced daily for 5 days). Breast tumour line HCC38 is not methylated for RASSF2, hence expression is unchanged after 5-aza-2dC treatment. Primers and conditions have been described previously (Hesson et al., 2005). cell lines (Figure 1a ). Direct sequencing confirmed these CoBRA results and demonstrated dense methylation across the region (Figure 1b) . Treatment with 5 0 -aza-2 0 deoxycytidine (5-aza-2dC) of tumour cell lines where RASSF2 was methylated and expression silenced reactivated RASSF2 expression, while no change in RASSF2 expression was seen in unmethylated tumour lines (Figure 1c ).
RASSF2 methylation analysis in breast, NSCLC and ovarian tumours
We had previously developed a methylation-specific PCR (MSP) assay to analyse RASSF2 methylation in colorectal tumours and adenomas (Hesson et al., 2005) . The same assay was utilized for analysing a series of breast, NSCLC and ovarian tumours for RASSF2 methylation. RASSF2 was found to be methylated in 38% (15/40) of breast tumours, and the corresponding normal DNA was unmethylated (n ¼ 10) (Figure 2a ). To determine the extent of methylation, CoBRA PCR was performed on three methylated and one unmethylated breast tumour and the PCR products were cloned and sequenced. Sequencing confirmed the extent of methylation of the promoter region in the methylated primary breast tumours, and revealed no methylation in samples deemed unmethylated by digestion. There was no correlation between RASSF2 methylation and breast tumour grade. We also analysed methylation status of RASSF1A in the same series of breast tumours. RASSF1A was methylated in 18 of 32 (56%) of these breast tumours. There was no correlation between RASSF1A and RASSF2 methylation status. RASSF2 was methylated in 44% (22/50) of NSCLC tumours (Figure 2b ). Where corresponding normal DNA was available it was not methylated, suggesting that the methylation was likely to be a tumour-specific event (Figure 2c ). Methylation was found at an equal frequency in all grades of tumour (I/II ¼ 7/16 (44%); IIIA ¼ 4/9 (44%); IV ¼ 10/23 (44%) and 1of 2 NSCLC of unknown grade was also methylated) suggesting that it is an early event in lung tumourigenesis. The methylation status of RASSF1A in this series of tumours had previously been determined (Agathanggelou et al., 2001) . There was no association between RASSF1A and RASSF2 methylation status.
We also analysed ovarian tumours for RASSF2 methylation using both MSP and CoBRA assays. None of the 17 ovarian tumours analysed demonstrated methylation of the Figure 2 Methylation status of the RASSF2 CpG island in primary tumours (T) and corresponding normal (N) tissue was determined by MSP where M represents methylation-specific PCR and U represents unmethylated-specific PCR. The primers and conditions have been described previously (Hesson et al., 2005) . (a) The RASSF2 CpG island promoter region was hypermethylated in 38% (15/40) primary breast tumours. The MCF7 cell line was used as a positive control for the M PCR, CT represents water control. (b) Methylation was found in 22/50 (44%) primary NSCLC tumours. (c) In NSCLC RASSF2 CpG island, methylation was tumour specific. (d) The RASSF2 CpG island promoter region was unmethylated in primary ovarian tumours. OVCA28, an ovarian tumour cell line partially methylated for RASSF2, acts as a positive control for both M and U sets of primers. RASSF2 CoBRA was also carried out on these samples to confirm the result (data not shown). (Figure 2d ). Since no methylation was found in ovarian tumours, we looked for mutations in the coding region of RASSF2 in these samples. No somatic inactivating mutations were found but one silent substitution was detected in exon 8 in two tumours. We also analysed methylation status of RASSF1A in the same series of ovarian tumours. RASSF1A was methylated in 10 of 17 (59%) of ovarian tumours respectively. This frequency of RASSF1A methylation in ovarian tumours is similar to that which has been reported previously (Yoon et al., 2001 ).
RASSF2 promoter CpG island

RASSF2 expression inhibits growth of breast cancer cells in vitro and in vivo
Previous studies have suggested that RASSF2 may function as a tumour suppressor gene in vitro in cell migration, cell cycle progression and colony formation assays (Vos et al., 2003; Akino et al., 2005; Zhang et al., 2007) , we have confirmed and extended this work by demonstrating that transfection of Flag-tagged wild-type RASSF2 into the MCF7 breast tumour cell line (where endogenous RASSF2 expression is lost by promoter methylation) reduces colony formation ability by 66% compared to cells transfected with the empty vector (P ¼ 0.0005, Figure 3a ). This effect was consistent through three independent experiments (similar results were obtained in breast tumour cell line HTB19). Two independent MCF7 clones stably expressing RASSF2 were generated (Cl.3 and Cl.4). These clones inhibited anchorage-independent growth in a soft agar assay (Cl.3 and Cl.4 vs vector Po0.05; Figures 3b and c) . Cells from these RASSF2-expressing clones were also inoculated in to SCID mice to study tumour growth in vivo. Each MCF7-RASSF2 stable clone (Cl.3 and Cl.4) was mixed with Matrigel and inoculated into three mice. As a control, MCF7 cells stably transfected with an empty vector were used (also with Matrigel; vector clones 1 or 2). Solid tumour nodes were only formed at the inoculation point and their size was measured with calipers. Over the course of 31-35 days, solid tumours were detected for all mice inoculated with the control MCF7 cells (vector clones 1 or 2) but no tumours were observed for mice inoculated with MCF7-RASSF2 cells (Cl.3 and Cl.4; Figure 3d ). This experiment was also done without Matrigel, when after 140 days no tumours were observed in mice inoculated with RASSF2-expressing clones 3 and 4 but tumours were formed within 120 days with vector control cells.
Thus we have demonstrated that RASSF2 can function as a tumour suppressor gene in vitro inhibiting the growth of breast cancer cell lines in colony formation and soft agar growth assays, and in vivo inhibiting tumour formation when cells expressing RASSF2 were subcutaneously injected into SCID mice. This is the first report demonstrating that RASSF2 can suppress tumour Values are the mean 7s.d. of three separate experiments each calculated from triplicate plates. The breast tumour cell line MCF7 was transfected with 2 mg of pFLAG or pFLAG-RASSF2 using 6 ml of FuGENE 6 (Roche, Burgess Hill, UK). Cells were selected with 600 mg ml À1 Geneticin (Gibco, Paisley, UK) in DMEM. Twenty-one days after transfection-surviving colonies were stained with 0.4% crystal violet. (b) Immunoblot stained with anti-FLAG (Sigma; clone M5) to detect RASSF2 in protein extracts from MCF7 cells stably transfected with pFLAG-RASSF2 (stable clones, Cl.3 and Cl.4). (c) Anchorage-independent growth studies. Growth of MCF7-RASSF2 stable clones (Cl.3 and Cl.4) and MCF7 cells stably transfected with an empty vector were compared using a soft agar assay. In a six-well plate a base layer of 2 ml growth medium containing 0.7% Noble agar was covered with 1 ml of growth medium containing 0.35% Noble agar and 5 Â 10 4 cells. Finally 2 ml growth medium containing 0.7% Noble agar was layered on top of the cells. After 35 days colonies comprised of at least 32 cells were counted on an inverted microscope. The number of colonies in cells transfected with empty vector was set at 100%. Values are the mean 7s.d. calculated from triplicate plates. (d) Tumour formation in SCID mice. Two different MCF7-RASSF2 stable clones were used for inoculation into SCID mice (Cl.3 and Cl.4). MCF7 cells stably transfected with an empty vector were used as a control (vectors 1 and 2). Tumourigenicity was assayed by s.c. injection as described by Protopopov et al. (2002) and Kashuba et al. (2004) . In brief 3 Â 10 6 cells in combination with Matrigel were inoculated into 4-to 8-week-old SCID mice. Three mice were used per construct and tumour growth in animals was checked twice a week, if tumour formation was observed, tumours were measured using calipers. Animals were maintained according to institutional guidelines.
cell growth in vivo hence providing further evidence for its role as a tumour suppressor gene.
RASSF2 contains a functional nuclear localization signal Bioinformatic analysis of RASSF2 was performed using PSORT (www.psort.org) and two putative nuclear localization signals (NLS) were predicted; a monopartite NLS of the pat 4 subcategory (RRHR between amino acids 165 and 168) and a bipartite NLS (Robbins et al., 1991) between amino acids 151 and 167. The two motifs of basic amino acids RR(N) 10 RIRRH are perfectly conserved among vertebrates Figure 4a , and the only alteration between vertebrates and in Xenopus converts an R to K thereby retaining the positive charge.
Therefore we generated a green fluorescent protein (GFP)-tagged RASSF2 and a version with basic amino acids within the bipartite NLS-mutated (R150A/R151A/ R152A) transfection of these constructs into Cos7 cells demonstrated predominantly nuclear localization of wild type ( Figure 4b ) and predominantly cytoplasmic localization of the mutant NLS (Figure 4c ). More than 65 cells from triplicate experiments were analysed for localization of the GFP signal, and the results are presented in Figure 4d . Similar results were obtained in HeLa and 293 cells, and the breast tumour cell lines MCF7 and HTB19 and also with FLAG-tagged RASSF2 constructs. The mutagenic primers were AGTGATGTTGGGGTGGCTGCCGCTGGCAATGTGAGGACG and CGTCCTCACATTGC-CAGCGGCAGCCACCCCAACATCACT). (d) Cos7 cells were transfected with GFP-RASSF2 or GFP-RASSF2 MtNLS and the localization scored as more intense in the nucleus, more intense in the cytoplasm or equal intensity. For each vector at each time point at least 65 cells were analysed. (e) Protein from H720 human lung cancer cell line was fractionated by standard CLB buffer protocol, and the blot immunoprobed with anti-RASSF2, (Vos et al., 2003) then reprobed with a-tubulin and TFIIH (Santa Cruz, Santa Cruz, CA, USA) to confirm that the nuclear and cytoplasmic fractions were free of contaminating cytoplasmic and nuclear proteins, respectively. (f) Growth in soft agar of HTB19 cells stably transfected with an empty vector was compared with HTB19 cells stably expressing RASSF2 or RASSF2 with a mutated NLS as described above except colonies were counted after 21 days. Asterisk (*) signifies Po0.05, evaluated by Student's t-test.
To confirm that the locilization was not due to an artefact of using the overexpressed tagged protein, the H720 lung cancer cell line was fractionated into nuclear and cytoplasmic portions, and the lysates subjected to immunoblotting using an antibody against RASSF2. This confirmed the predominant nuclear localization of endogenous RASSF2 (Figure 4e ).
HTB19 clones stably expressing RASSF2 or MtNLS were generated and while expression of RASSF2 was able to suppress anchorage-independent growth by 56% compared to cells transfected with the empty vector (Po0.05), cells expressing MtNLS showed a much smaller (17%) reduction in ability to form colonies in soft agar compared with the empty vector. When compared with cells expressing RASSF2 with the MtNLS, cells expressing wild-type RASSF2 suppressed growth by 47% (Po0.05; Figure 4f ). This suggests that the nuclear localization of RASSF2 is important for its function as a tumour suppressor.
The data presented in this study and our previously published work (Hesson et al., 2005) demonstrate that methylation of the RASSF2 promoter is an early and a frequent event in a range of epithelial-derived tumours (including NSCLC, breast and colorectal cancers). Thus RASSF2 promoter methylation shows potential as a biologically relevant biomarker for the early detection of these cancers and for developing novel therapeutic intervention regimes. We also demonstrate that RASSF2 can function as a TSG both in vitro and in vivo and has a functional NLS that is important for its tumour suppressor gene function(s).
